Citalopram Pharmacogenetics - Genetic Drug Testing Gene2Rx

Drug Overview

Citalopram, marketed under the brand names Celexa, Cipralex, and Lexapro, is a prescription antidepressant belonging to the selective serotonin reuptake inhibitor (SSRI) class.

It is primarily used to treat major depressive disorder and various anxiety disorders. By blocking the serotonin transporter, citalopram increases serotonin levels in the brain to help improve mood and reduce anxiety symptoms.

The drug is metabolized in the liver by enzymes including CYP2C19 into less active metabolites, which are then excreted by the kidneys.

Relevant Genes and Their Roles

CYP2C19 is the key enzyme responsible for converting citalopram into its primary inactive metabolite, desmethylcitalopram. Genetic variants in the CYP2C19 gene can speed up or slow down this process.

These variants assign your CYP2C19 phenotype as ultrarapid, rapid, normal, intermediate, or poor. Faster metabolism lowers drug levels and risks under-treatment; slower metabolism raises levels and brings more side effects.

Impact of Genetics on Drug Response

Patients with ultrarapid or rapid CYP2C19 phenotypes may clear citalopram too quickly, leading to reduced drug exposure and diminished clinical benefit. Conversely, intermediate or poor metabolizers may have elevated plasma concentrations, increasing the likelihood of side effects such as QT prolongation. Normal metabolizers are expected to achieve standard therapeutic levels and response.

Expected Clinical Effects of Genetic Variation

Ultrarapid Metabolizer

Effect on drug levels: Significantly decreased plasma concentrations.
Clinical consequence: Reduced likelihood of therapeutic benefit.
Side effects: Lower risk of common SSRI side effects; typically mild when present.

Rapid Metabolizer

Effect on drug levels: Decreased plasma concentrations.
Clinical consequence: Possible reduced efficacy requiring dose adjustment.
Side effects: Slightly lower frequency of side effects; generally mild.

Normal Metabolizer

Effect on drug levels: Expected therapeutic plasma concentrations.
Clinical consequence: Standard therapeutic response.
Side effects: Typical SSRI side effect profile; mild to moderate frequency.

Intermediate Metabolizer

Effect on drug levels: Increased plasma concentrations.
Clinical consequence: Heightened risk of dose-related side effects.
Side effects: Moderate severity (e.g., nausea, headache); may occur more frequently.

Poor Metabolizer

Effect on drug levels: Substantially increased plasma concentrations.
Clinical consequence: Increased risk of adverse reactions and toxicity (e.g., QT prolongation).
Side effects: Severe or more frequent side effects such as dizziness and cardiac conduction changes.

Indeterminate/Not Available

Effect on drug levels: Unknown.
Clinical consequence: No specific guidance; follow standard dosing with clinical monitoring.
Side effects: Unknown; monitor patient accordingly.

Dosing Guidelines

The following dosing guidelines are based on CPIC recommendations for citalopram and the CYP2C19 genotype.

CYP2C19 Dosing Guideline

Phenotype	Clinical Consequence	Guideline Recommendation
Ultrarapid Metabolizer	Lower plasma concentrations; reduced efficacy.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram is used and efficacy is insufficient, titrate to a higher maintenance dose.
Rapid Metabolizer	Lower plasma concentrations; reduced efficacy.	Initiate therapy at the recommended starting dose. If response is inadequate, consider titrating to a higher maintenance dose or switching to an alternative antidepressant not predominantly metabolized by CYP2C19.
Normal Metabolizer	Normal metabolism; expected therapeutic response.	Initiate therapy with the recommended starting dose.
Intermediate Metabolizer	Higher plasma concentrations; increased side effect risk.	Initiate therapy with the recommended starting dose. Consider a slower titration schedule and lower maintenance dose than for normal metabolizers.
Likely Intermediate Metabolizer	Higher plasma concentrations; increased side effect risk.	Initiate therapy with the recommended starting dose. Consider a slower titration schedule and lower maintenance dose than for normal metabolizers.
Likely Poor Metabolizer	Higher plasma concentrations; increased side effect risk.	Consider an alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram is used, start at a lower dose, use slower titration, and reduce standard maintenance dose by 50%.
Poor Metabolizer	Higher plasma concentrations; increased side effect risk.	Consider an alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram is used, start at a lower dose, use slower titration, and reduce standard maintenance dose by 50%.
Indeterminate	Unknown impact.	Initiate therapy with recommended starting dose.
Not available	Unknown impact.	Initiate therapy with recommended starting dose.

Alternative Treatment Options

The CPIC guideline suggests considering antidepressants not predominantly metabolized by CYP2C19, such as sertraline or paroxetine, as alternative treatment options. Other classes like SNRIs (e.g., venlafaxine) may also be considered depending on clinical context. These are examples only and not a substitute for professional medical advice.

Sources and References

Considering GeneSight for this medication?

Gene2Rx uses the same CPIC and FDA guidelines as GeneSight, covers more medications, costs $5-$49 instead of several hundred, and works with the 23andMe or AncestryDNA data you may already have. See the full side-by-side comparison before ordering.

Read the comparison →

Genes that affect Citalopram

See the full list of drugs affected by each gene:

CYP2C19

Cytochrome P450 2C19

Brand names containing Citalopram

See how your genetics affect each product Citalopram shows up in:

Celexa

Brand of citalopram

Related Guides

Learn more about how genetics may affect your response to Citalopram and related medications: